Patients with β-thalassemia major have extremely low vitamin D levels, owing to reduced intestinal absorption, subicteric tint, and/or iron-induced higher pigmentation. We investigated whether some polymorphisms within the VDR, CYP24A1, CYP27B1, and GC genes could play a role in deferasirox pharmacokinetics in a cohort of pediatric patients.
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children
ALLEGRA, SARAH
First
;CUSATO, JESSICA;DE FRANCIA, SILVIA;LONGO, Filomena;PIRRO, Elisa;MASSANO, DAVIDE;PIGA, Antonio GiulioCo-last
;D'AVOLIO, ANTONIOCo-last
2018-01-01
Abstract
Patients with β-thalassemia major have extremely low vitamin D levels, owing to reduced intestinal absorption, subicteric tint, and/or iron-induced higher pigmentation. We investigated whether some polymorphisms within the VDR, CYP24A1, CYP27B1, and GC genes could play a role in deferasirox pharmacokinetics in a cohort of pediatric patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
01213011-900000000-99221.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
164.78 kB
Formato
Adobe PDF
|
164.78 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
